1. Cardiogenic shock management January 14 th, 2016 10h30-12h

2. About the aetiologies of cardiogenic shock, which proposition(s) is/are correct? A) Myocardial infarction is responsible for ≈ 40% B) Myocardial infarction is responsible for ≈ 75% C) The 2 nd leading cause is pulmonary embolism D) The 2 nd leading cause is acute myocarditis E) The ischemic aetiology has decreased from 50% in 30 years

3. About the aetiologies of cardiogenic shock, which proposition(s) is/are correct? A) Myocardial infarction is responsible for ≈ 40% B) Myocardial infarction is responsible for ≈ 75% C) The 2 nd leading cause is pulmonary embolism D) The 2 nd leading cause is acute myocarditis E) The ischemic aetiology has decreased from 50% in 30 years

4. What is/are the predictive factor(s) of poor prognosis in cardiogenic shock? A) Diabetes B) Renal insufficiency C) Older age D) Use of vasopressors and inotropes E) Atrial fibrillation onset

5. What is/are the predictive factor(s) of poor prognosis in cardiogenic shock? A) Diabetes B) Renal insufficiency C) Older age D) Use of vasopressors and inotropes E) Atrial fibrillation onset

6. Mortality of cardiogenic shock: A) Is ≈ 45% B) Is ≈ 20% C) Has decreased over the past 20 years D) Is higher in case of non ischemic versus ischemic cause E) Is mostly due to liver failure

7. Mortality of cardiogenic shock: A) Is ≈ 45% B) Is ≈ 20% C) Has decreased over the past 20 years D) Is higher in case of non ischemic versus ischemic cause E) Is mostly due to liver failure

8. About Serelaxin, which of the following proposition(s) is/are correct? A) Is a recombinant form of the human Relaxin hormone B) Serelaxin is produced during a normal pregnancy C) Is a potent vasodilator D) Has major diuretic effects E) Has shown improved survival in acute heart failure with reduced LVEF

9. About Serelaxin, which of the following proposition(s) is/are correct? A) Is a recombinant form of the human Relaxin hormone B) Serelaxin is produced during a normal pregnancy C) Is a potent vasodilator D) Has major diuretic effects E) Has shown improved survival in acute heart failure with reduced LVEF

10. About Ularitide, which of the following proposition(s) is/are correct? A) Is a myosin activator B) Is a synthetic analogous of the human natriuretic peptide urodilatin C) His main target is in the renal collecting tubules D) Could decrease renin-angiotensinaldosterone system (RAAS) activation E) TRUE-AHF is a phase III multicentre randomised clinical trial evaluating the efficacy and safety of Ularitide

11. About Ularitide, which of the following proposition(s) is/are correct? A) Is a myosin activator B) Is a synthetic analogous of the human natriuretic peptide urodilatin C) His main target is in the renal collecting tubules D) Could decrease renin-angiotensinaldosterone system (RAAS) activation E) TRUE-AHF is a phase III multicentre randomised clinical trial evaluating the efficacy and safety of Ularitide

12. What is/are the ventricular assistance device(s) that can be used in cardiogenic shock? A) Intra-Aortic Balloon Pump (IABP) B) The Impella C) The TandemHeart system D) veno-venous ECMO E) Veno-arterial ECMO

13. What is/are the ventricular assistance device(s) that can be used in cardiogenic shock? A) Intra-Aortic Balloon Pump (IABP) B) The Impella C) The TandemHeart system D) veno-venous ECMO E) Veno-arterial ECMO

14. Which of the following proposition(s) is/are contra-indication(s) to ECMO? A) Severe Mitral regurgitation B) Severe aortic regurgitation C) Intracardiac thrombus D) On going sepsis E) Severe Right ventricular dysfunction

15. Which of the following proposition(s) is/are contra-indication(s) to ECMO? A) Severe Mitral regurgitation B) Severe aortic regurgitation C) Intracardiac thrombus D) On going sepsis E) Severe Right ventricular dysfunction